IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF SOUTH CAROLINA CHARLESTON DIVISION

| IN RE: LIPITOR (ATORVASTATIN CALCIUM) MARKETING, SALES |)) MDL No. 2:14-mn-02502-RMG |
|-----------------------------------------------------------|-----------------------------------------------------------------------|
| PRACTICES AND PRODUCTS LIABILITY LITIGATION |) CASE MANAGEMENT ORDER NO. 56 |
| |) This Order relates to <i>Daniels v. Pfizer</i> , 2:14-) cv-1400 |
| |) |
| |) |

The Court has allowed Plaintiffs to submit supplemental reports and ordered supplemental briefing on the issue of general causation at various dosages of Lipitor. (CMO 49, Dkt. No. 1197). This supplemental briefing will be completed on February 19, 2016. (*See* CMO 50, Dkt. No. 1230). The Court cannot rule on Pfizer's motion to exclude the testimony of Plaintiffs' general causation experts (Dkt. No. 972) or on the motions for summary judgment in the two bellwether cases, *Daniels v. Pfizer*, 2:14-cv-1400 and *Hempstead v. Pfizer*, 2:14-cv-1879, (Dkt. Nos. 1010, 1232), until this briefing is completed. Therefore, the trial date in *Daniels v. Pfizer*, 2:14-cv-1400 is **VACATED** and will be reset, if needed, after the Court addresses Pfizer's motion for summary judgment in the case.

AND IT IS SO ORDERED.

Richard Mark Gerge

December <u>(1</u>, 2015 Charleston, South Carolina